The HPV Vaccine: Access and Use in the U.S.
-
By
-
kffbryanacs
-
April 8, 2026
-
Clinical Scorecard: Utilization and Availability of the HPV Vaccine in the United States
At a Glance
| Category | Detail |
|---|
| Condition | Human Papillomavirus (HPV) and associated cancers |
| Key Mechanisms | Prevention of HPV infection and related cancers through vaccination |
| Target Population | Individuals aged 9 to 45 years, including all genders |
| Care Setting | Primary care and vaccination clinics |
Key Highlights
- HPV vaccine reduces risk of HPV-related cancers, including cervical, anal, and oropharyngeal cancers.
- Gardasil®9 is the only HPV vaccine available in the U.S., covering 9 HPV strains.
- Vaccination rates have declined since the COVID-19 pandemic.
- Racial disparities exist in cervical cancer incidence and mortality rates.
- The vaccine is fully covered by private insurance and public programs.
Guideline-Based Recommendations
Diagnosis
- HPV infections are diagnosed through screening methods such as Pap tests.
Management
- Administer Gardasil®9 to adolescents in a two-dose series before sexual activity.
Monitoring & Follow-up
- Monitor vaccination uptake and cervical cancer screening rates.
Risks
- Individuals with a history of cervical cancer or immunosuppression are at higher risk for anal cancer.
Patient & Prescribing Data
Individuals aged 9 to 45 years, including boys and girls.
Vaccination can prevent infection against HPV strains not previously contracted.
Clinical Best Practices
- Promote HPV vaccination before the initiation of sexual activity.
- Address racial disparities in cervical cancer screening and treatment.
- Educate patients on the benefits of the HPV vaccine.
References
